Feasibility of Inpatient Continuous Glucose Monitoring During the COVID-19 Pandemic: Early Experience
Sirimon Reutrakul, Matthew Genco, Harley Salinas, Robert M. Sargis, Carlie Paul, Yuval Eisenberg, Jiali Fang, Rachel Caskey, Sarah Henkle, Sam Fatoorehchi, Amanda Osta, Pavan Srivastava, Alexia Johnson, Sarah E. Messmer, Michelle Barnes, Sarida Pratuangtham, Brian T. Layden
Abstract
Continuous glucose monitoring (CGM) systems have been explored in a few studies for non-intensive care unit (ICU) patients (1-3). During the coronavirus disease 2019 (COVID-19) pandemic, shortage of personal protective equipment (PPE) became a concern. On 1 April 2020, the U.S. Food and Drug Administration announced it would not object to the use of CGM systems to assist with COVID-19 patient monitoring (4). This study was conducted to explore the feasibility of using CGM in noncritically ill patients hospitalized with COVID-19.